SARS-CoV-2 Nucleocapsid MAb (Clone 1035111)

Catalog # Availability Size / Price Qty
Detection of SARS-CoV-2 Nucleocapsid by Western Blot.
2 Images
Product Details
Citations (5)
Supplemental Products

SARS-CoV-2 Nucleocapsid MAb (Clone 1035111) Summary

Species Reactivity
Detects SARS-CoV-2 Nucleocapsid in direct ELISAs and Western blots. No cross-reactivity with MERS Nucleocapsid is observed in Western blots.
Monoclonal Mouse IgG2B Clone # 1035111
Protein A or G purified from hybridoma culture supernatant
Spodoptera frugiperda, Sf 21-derived SARS-CoV-2 Nucleocapsid protein
Accession # YP_009724397.2
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.


Recommended Concentration
Western Blot
2 µg/mL
Recombinant SARS-CoV-2 Nucleocapsid protein
5-25 µg/mL
Immersion fixed paraffin-embedded sections of SARS-CoV-2 infected human lung

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot Detection of SARS-CoV-2 Nucleocapsid antibody by Western Blot. View Larger

Detection of SARS-CoV-2 Nucleocapsid by Western Blot. Western blot shows recombinant SARS-CoV-2 Nucleocapsid protein. PVDF membrane was probed with 2 µg/mL of Mouse Anti-SARS-CoV-2 Nucleocapsid Monoclonal Antibody (Catalog # MAB10474) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF018). A specific band was detected for SARS-CoV-2 Nucleocapsid at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

Immunohistochemistry View Larger

SARS-CoV-2 Nucleocapsid in SARS-CoV-2 Infected Human Lung. SARS-CoV-2 Nucleocapsid was detected in immersion fixed paraffin-embedded sections of SARS-CoV-2 infected human lung (left, positive staining) and normal human lung (right, negative control) using Mouse Anti-SARS-CoV-2 Nucleocapsid Monoclonal Antibody (Catalog # MAB10474) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to SARS-CoV-2 infected cells. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Preparation and Storage

Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Size / Price
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Nucleocapsid

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1).  While the S, E and M proteins build up the viral envelop, the N protein is involved transcription, replication and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (2, 3).  The SARS-CoV-2 N protein is a ~45 kDa protein composed of two independent structural domains connected by a linker region. The N-terminal region contains an RNA binding domain, the linker region interacts with the M protein and the C-terminal region contains a self-association domain (2,3). The SARS-CoV2 N protein shares 91% and 47% amino acid sequence identity with SARS-CoV-1 and MERS N protein, respectively.  The SARS-CoV-2 N protein displays VSR (viral suppressor of RNA interference) activity in mammalian cells (4). In addition, the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity (5, 6), so it has been used to develop serological diagnostic kit for Covid-19 IgM and IgG antibody tests (7).

  1. Wu, F. et al. (2020) Nature 579:265.
  2. Chang, C. K. et al. (2006) J. Biomed. Sci. 13:59.
  3. Hurst, K. R. et al. (2009) J. Virol. 83:7221.
  4. Mu, J. et al. (2020) Sci. China Life Sci. doi: 10.1007/s11427-020-1692-1.
  5. Che, X. Y. et al. (2004) J. Clin. Microbiol. 42:2629.
  6. Guan, M. et al. (2004) Clin. Diagn. Lab. Immunol. 11:287.
  7. Liu, W. et al. (2020) J. Clin. Microbiol. doi: 10.1128/JCM.00461-20.
Long Name
Nucleocapsid Protein
Entrez Gene IDs
918763 (HCoV-229E); 3200423 (HCoV-HKU1); 2943504 (HCoV-NL63); 39105221 (HCoV-OC43); 14254601 (MERS-CoV); 1489678 (SARS-CoV); 43740575 (SARS-CoV-2)
Alternate Names
N Protein; Nucleocapsid

Product Datasheets

You must select a language.


Citations for SARS-CoV-2 Nucleocapsid MAb (Clone 1035111)

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Filter by:

  1. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
    Authors: Tamura, T;Ito, J;Uriu, K;Zahradnik, J;Kida, I;Anraku, Y;Nasser, H;Shofa, M;Oda, Y;Lytras, S;Nao, N;Itakura, Y;Deguchi, S;Suzuki, R;Wang, L;Begum, MM;Kita, S;Yajima, H;Sasaki, J;Sasaki-Tabata, K;Shimizu, R;Tsuda, M;Kosugi, Y;Fujita, S;Pan, L;Sauter, D;Yoshimatsu, K;Suzuki, S;Asakura, H;Nagashima, M;Sadamasu, K;Yoshimura, K;Yamamoto, Y;Nagamoto, T;Schreiber, G;Maenaka, K;Genotype to Phenotype Japan (G2P-Japan) Consortium, ;Hashiguchi, T;Ikeda, T;Fukuhara, T;Saito, A;Tanaka, S;Matsuno, K;Takayama, K;Sato, K;
    Nature communications
    Species: Syrian Hamster
    Sample Types: Whole Tissue
    Applications: IHC
  2. Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein
    Authors: R Otsubo, T Minamitani, K Kobiyama, J Fujita, T Ito, S Ueno, I Anzai, H Tanino, H Aoyama, Y Matsuura, K Namba, KI Imadome, KJ Ishii, K Tsumoto, W Kamitani, T Yasui
    Scientific Reports, 2022-11-22;12(1):20120.
    Species: Hamster
    Sample Types: Whole Tissue
    Applications: IHC
  3. Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody
    Authors: T Sulea, J Baardsnes, M Stuible, N Rohani, A Tran, M Parat, Y Cepero Don, M Duchesne, P Plante, G Kour, Y Durocher
    PLoS ONE, 2022-03-30;17(3):e0266250.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  4. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
    Authors: R Suzuki, D Yamasoba, I Kimura, L Wang, M Kishimoto, J Ito, Y Morioka, N Nao, H Nasser, K Uriu, Y Kosugi, M Tsuda, Y Orba, M Sasaki, R Shimizu, R Kawabata, K Yoshimatsu, H Asakura, M Nagashima, K Sadamasu, K Yoshimura, Genotype t, H Sawa, T Ikeda, T Irie, K Matsuno, S Tanaka, T Fukuhara, K Sato
    Nature, 2022-02-01;0(0):.
    Species: Hamster
    Sample Types: Whole Tissue
    Applications: IHC
  5. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
    Authors: A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, K Shirakawa, K Sadamasu, I Kimura, J Ito, J Wu, K Iwatsuki-H, M Ito, S Yamayoshi, S Loeber, M Tsuda, L Wang, S Ozono, EP Butlertana, YL Tanaka, R Shimizu, K Shimizu, K Yoshimatsu, R Kawabata, T Sakaguchi, K Tokunaga, I Yoshida, H Asakura, M Nagashima, Y Kazuma, R Nomura, Y Horisawa, K Yoshimura, A Takaori-Ko, M Imai, Genotype t, S Tanaka, S Nakagawa, T Ikeda, T Fukuhara, Y Kawaoka, K Sato
    Nature, 2021-11-25;0(0):.
    Species: Hamster
    Sample Types: Whole Tissue
    Applications: IHC


No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for SARS-CoV-2 Nucleocapsid MAb (Clone 1035111)

There are currently no reviews for this product. Be the first to review SARS-CoV-2 Nucleocapsid MAb (Clone 1035111) and earn rewards!

Have you used SARS-CoV-2 Nucleocapsid MAb (Clone 1035111)?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review